BeiGene
Pipeline
We are advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. We have three internally-developed late-stage assets, five marketed products in China and one marketed product in the U.S.
- Global
- China
Zanubrutinib BGB-3111, BTK Info Trials
A small molecule inhibitor of Bruton’s tyrosine kinase, or BTK, that is currently being evaluated in a broad pivotal clinical program globally, and in China as a potential monotherapy and in combination with other therapies to treat various forms of lymphoma. Zanubrutinib’s early compound name was BGB-3111.
Commercial Rights
BeiGene, Worldwide
Partnerships
Tislelizumab BGB-A317, PD-1 Info Trials
An investigational humanized monoclonal antibody against the immune checkpoint receptor PD-1 that is currently being evaluated in pivotal clinical trials globally and in China, as a monotherapy and in combination with standard of care to treat various solid and hematological cancers. Tislelizumab is designed to bind to and block downstream activity of PD-1, a cell surface receptor that plays an important role in downregulating the immune system by preventing the activation of T‑cells. Tislelizumab’s early compound name was BGB-A317.
Commercial Rights
BeiGene
Partnerships
Pamiparib BGB-290, PARP Info Trials
An investigational small molecule inhibitor of the PARP1 and PARP2 enzymes that is being evaluated as a potential monotherapy and in combination with other therapies to treat various solid tumors. Pamiparib’s early compound name was BGB-290.
Commercial Rights
BeiGene
Partnerships
Lifirafenib BGB-283, RAF DIMER Info Trials
An investigational novel small molecule inhibitor with RAF monomer and dimer inhibition activities. Lifirafenib’s early compound name was BGB-283.
Commercial Rights
BeiGene
Partnerships
Ociperlimab BGB-A1217, TIGIT Info Trials
Ociperlimab is an investigational TIGIT monoclonal antibody discovered by BeiGene scientists.
Commercial Rights
BeiGene
Partnerships
REVLIMID® LENALIDOMIDE/IMiD Info Trials
REVLIMID® (lenalidomide) is an oral immunomodulatory drug that was approved in China in 2013 for the treatment of multiple myeloma in combination with dexamethasone, in adult patients who have received at least one prior therapy. In 2018, REVLIMID® received approval in China of a new indication for the treatment of MM in combination with dexamethasone, in adult patients with previously untreated MM who are not eligible for transplant.
Commercial Rights
BeiGene has exclusive license from Celgene to market REVLIMID® in China
Partnerships
ABRAXANE® ALBUMIN-BOUND PACLITAXEL Info Trials
ABRAXANE® (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy product, which was developed using Celgene’s proprietary nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. In China, ABRAXANE® is approved for metastatic breast cancer after failure of combination chemotherapy for metastatic disease, or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Commercial Rights
BeiGene has exclusive license from Celgene to market ABRAXANE® in China
Partnerships
VIDAZA® HYPOMETHYLATING AGENT Info Trials
VIDAZA® (azacitidine for injection) is a pyrimidine nucleoside analog that has been shown to reverse the effects of DNA hypermethylation and promote subsequent gene re-expression. VIDAZA® was approved in China in 2017 for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, or MDS, chronic myelomonocyte leukemia, or CMML, and acute myeloid leukemia, or AML, with 20% to 30% blasts and multi-lineage dysplasia.
Commercial Rights
BeiGene has exclusive license from Celgene to market VIDAZA® in China
Partnerships
Avadomide CC-122, CELMoD Info Trials
CC-122 is an investigational next‑generation Cereblon modulator currently in clinical development by Celgene. It is being evaluated in clinical trials, both as a single agent and in combination, for hematological and solid tumor cancers.
Commercial Rights
BeiGene has exclusive development and commercialization rights in China from Celgene
Partnerships
Sitravatinib MULTI-KINASE INHIBITOR Info Trials
Sitravatinib is an investigational spectrum-selective kinase inhibitor which potently inhibits receptor tyrosine kinases, including RET, TAM family receptors (TYRO3, Axl, MER), and split family receptors (VEGFR2, KIT).
Commercial Rights
BeiGene has an exclusive license agreement for the development, manufacturing, and commercialization of Mirati’s sitravatinib in Asia (excluding Japan and certain other countries), Australia, and New Zealand.
Partnerships
Zanidatamab ZW25, BISPECIFIC ANTIBODY Info Trials
Zanidatamab (ZW25) is an investigational bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2 resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function.
Commercial Rights
BeiGene has exclusive development and commercial rights in Asia (excluding Japan), Australia and New Zealand from Zymeworks Inc.
Partnerships
ZW49 BISPECIFIC ADC Info Trials
ZW49 is a novel bispecific ADC targeting two non-overlapping epitopes of HER2 resulting in enhanced internalization and delivery of its proprietary ZymeLink cytotoxic payload. ADCs incorporating ZymeLink have demonstrated a greater therapeutic window (range of doses that are both efficacious and tolerable) in preclinical testing than those incorporating the commonly used ADC payloads DM1 or MMAE.
Commercial Rights
BeiGene has exclusive development and commercial rights in Asia (excluding Japan), Australia and New Zealand from Zymeworks Inc.
Partnerships
BGB-3245 RAF DIMER INHIBITOR Info Trials
BGB-3245 is an investigational RAF dimer inhibitor with activity against mutant monomeric and dimeric forms of B-RAF in preclinical studies.
Commercial Rights
BeiGene has exclusive commercial rights in Asia (ex-Japan).
Partnerships
* Some indications will not require a non-pivotal Phase 2 clinical trial prior to beginning pivotal Phase 2 or 3 clinical trials.
** Confirmatory clinical trials post-approval are required for accelerated approvals.
1 GAZYVA® is a registered trademark of Genentech.
2 Celgene has the right to develop and commercialize tislelizumab in solid tumors in the United States, European Union, Japan, and the rest-of-world outside of Asia.
3 ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation. BeiGene markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.
4 Partnership with Mirati Therapeutics, Inc.
5 Collaboration with Zymeworks Inc.
ABBREVIATIONS
1L/2L/3L = first, second or third line; AML = acute myeloid leukemia; BC = breast cancer; BR = bendamustine and rituximab; cHL = classical Hodgkin's lymphoma; CLL = chronic lymphocytic leukemia; CMMoL = chronic myelomonocytic leukemia; DLBCL = diffuse large B cell lymphoma; ESCC = esophageal squamous cell carcinoma; FL = follicular lymphoma; GC = gastric cancer; GEA = gastroesophageal adenocarcinoma; GEJC = gastroesophageal junction cancer; HCC = hepatocellular carcinoma; cHL = classic Hodgkin’s lymphoma; MCL = mantle cell lymphoma; mCRPC = metastatic castration resistant prostate cancer; MDS = myelodysplastic syndrome; MM = multiple myeloma; MZL = marginal zone lymphoma; NK = natural killer; NHL = non-Hodgkin’s lymphoma; NSCLC = non-small cell lung cancer; OC = ovarian cancer; R = rituximab; R/R = relapsed/refractory; RT = radiation therapy; SCLC = small cell lung cancer; SLL = small lymphocytic leukemia; TMZ = temozolomide; TN = treatment-naive; UC = urothelial carcinoma; WM = Waldenstrom macroglobulinemia.
Last Updated: July13, 2020
